Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valeria Cagno

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Journal of Virology|March 2, 2026
Challenges in developing broad-spectrum viral attachment inhibitors targeting heparan sulfates and sialic acidsValeria Cagno
International Journal of Molecular Sciences|September 9, 2023
Small Molecules Targeting Viral RNAGregory Mathez, Valeria Cagno
Computer Communications|November 25, 2020
Do we need a contact tracing app?Leonardo Maccari, Valeria Cagno
Microorganisms|July 2, 2021
Viruses Like Sugars: How to Assess Glycan Involvement in Viral AttachmentGregory Mathez, Valeria Cagno
Antiviral Chemistry & Chemotherapy|November 22, 2021
Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testingGregory Mathez, Valeria Cagno
Journal of Chemical Information and Modeling|July 22, 2024
Novel Inhibitors of SARS-CoV-2 RNA Identified through Virtual ScreeningGregory Mathez, Andrea Brancale, Valeria Cagno
Viruses|January 21, 2023
Alpha and Omicron SARS-CoV-2 Adaptation in an Upper Respiratory Tract ModelGregory Mathez, Trestan Pillonel, Claire Bertelli, et al.
Molecular Aspects of Medicine|April 18, 2016
Oxysterols: An emerging class of broad spectrum antiviral effectorsDavid Lembo, Valeria Cagno, Andrea Civra, et al.
Basic & Clinical Pharmacology & Toxicology|November 24, 2020
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitroValeria Cagno, Gaelle Magliocco, Caroline Tapparel, et al.
Antiviral Research|February 8, 2025
Targeting PI4KB and Src/Abl host kinases as broad-spectrum antiviral strategy: Myth or real opportunity?Maria Grazia Martina, Daniele Rubini, Marco Radi, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Journal of Virology|March 2, 2026
Challenges in developing broad-spectrum viral attachment inhibitors targeting heparan sulfates and sialic acidsValeria Cagno
International Journal of Molecular Sciences|September 9, 2023
Small Molecules Targeting Viral RNAGregory Mathez, Valeria Cagno
Computer Communications|November 25, 2020
Do we need a contact tracing app?Leonardo Maccari, Valeria Cagno
Microorganisms|July 2, 2021
Viruses Like Sugars: How to Assess Glycan Involvement in Viral AttachmentGregory Mathez, Valeria Cagno
Antiviral Chemistry & Chemotherapy|November 22, 2021
Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testingGregory Mathez, Valeria Cagno
Journal of Chemical Information and Modeling|July 22, 2024
Novel Inhibitors of SARS-CoV-2 RNA Identified through Virtual ScreeningGregory Mathez, Andrea Brancale, Valeria Cagno
Viruses|January 21, 2023
Alpha and Omicron SARS-CoV-2 Adaptation in an Upper Respiratory Tract ModelGregory Mathez, Trestan Pillonel, Claire Bertelli, et al.
Molecular Aspects of Medicine|April 18, 2016
Oxysterols: An emerging class of broad spectrum antiviral effectorsDavid Lembo, Valeria Cagno, Andrea Civra, et al.
Basic & Clinical Pharmacology & Toxicology|November 24, 2020
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitroValeria Cagno, Gaelle Magliocco, Caroline Tapparel, et al.
Antiviral Research|February 8, 2025
Targeting PI4KB and Src/Abl host kinases as broad-spectrum antiviral strategy: Myth or real opportunity?Maria Grazia Martina, Daniele Rubini, Marco Radi, et al.
Pageof 7